Skip to main content

Table 2 Distribution of mRS scores on day 90 after treatment (full analysis set)

From: Efficacy and safety of cinepazide maleate injection in patients with acute ischemic stroke: a multicenter, randomized, double-blind, placebo-controlled trial

 

Cinepazide maleate

(n = 466)

Placebo

(n = 471)

P

Z

mRS score at 90 days

  

0.009

−2.595

 Level 0

67 (14.4)

69 (14.7)

 Level 1

139 (29.8)

107 (22.7)

 Level 2

78 (16.7)

60 (12.7)

 Level 3

91 (19.5)

139 (29.5)

 Level 4

39 (8.4)

43 (9.1)

 Level 5

2 (0.4)

7 (1.5)

  ≤ level 2

284 (60.9)

236 (50.1)

0.0004

0.607 (0.460, 0.801)a

Missing (did not complete the study)

50 (10.7)

46 (9.8)

  
  1. Data are presented as n (%)
  2. CI confidence interval, mRS modified Rankin scale, Z Z statistic
  3. p value and Z statistic are from two independent sample rank sum tests
  4. aOdds ratio (95% confidence interval)